30 closest matches · ranked by relevance
Atypical Hemolytic-Uremic Syndrome
Primary: Percentage of Patients With Complete TMA Response — 73.2 Percentage of Participants
Atypical Hemolytic-Uremic Syndrome
Primary: Proportion of Patients With Complete TMA Response — 63.6 Percentage of Participants
Thrombotic Microangiopathies · Atypical Hemolytic Uremic Syndrome · Multiple Organ Dysfunction Syndrome
Primary: Survival — 15 Participants — p=<0.0001
Atypical Hemolytic Uremic Syndrome
Primary: Percentage of Patients With TMA Event-free Status — 80 Percentage of Participants
Atypical Hemolytic Uremic
Primary: Percentage of Participants With a Complete Thrombotic Microangiopathy (TMA) Response — 64.0 percentage of participants
Atypical Hemolytic Uremic Syndrome (aHUS)
Primary: Percentage Of Complement Inhibitor Treatment-naïve Participants With Complete Thrombotic Microangiopathy (TMA) Response at Week 26 — 77.8; 94.4; 88.9; 83.3 percentage of…
Atypical Hemolytic Uremic Syndrome
Primary: Percentage of Patients With TMA Event-free Status — 80 Percentage of Participants
Atypical Hemolytic Uremic Syndrome
Primary: Platelet Count Change From Baseline to 26 Weeks — 65.18 10^9 cells/L — p=<0.0001
Atypical Hemolytic Uremic Syndrome
Primary: Platelet Count Change From Baseline to 26 Weeks — 65.18 10^9 cells/L — p=<0.0001
Atypical Hemolytic Uremic Syndrome (aHUS)
Primary: Percentage Of Participants With Complete Thrombotic Microangiopathy (TMA) Response at Week 26 — 53.6; 83.9; 76.8; 58.9 percentage of participants
Antiphospholipid Antibody Syndrome · End Stage Renal Disease
Primary: Number of Patients With Prevention of Catastrophic Antiphospholipid Antibody Syndrome (CAPS) After Kidney Transplant — 1 Participants
Kidney Transplant
Primary: Number of Subjects With Antibody-Mediated Rejection (AMR) in the First 3 Months After Living Donor Kidney Transplantation — 2 Participants
Diarrhea Bloody
Primary: Blood Test Performance — 18; 17 Participants
Thrombotic Microangiopathies
Primary: Percent of Total Doses of Defibrotide That Were Missed [Feasibility] — 0.7 percentage of missed doses
Kidney; Complications, Allograft
Primary: Baseline eGFR (Estimated Glomerular Filtration Rate) — 30.04; 30.04 mL/min/1.73 m2
Thrombotic Microangiopathies
Primary: Assess the Safety and Tolerability of Multiple-dose Administration of OMS721 in Participants With TMA — 0; 0; 27 Participants
Antithrombin III Deficiency
Primary: Incidence of Thromboembolic Events Acute Deep Venous Thrombosis (DVT) and/or Thromboembolic Events Other Than Acute Deep Venous Thrombosis (DVT) — 0 Participants
Dense Deposit Disease · Membranoproliferative Glomerulonephritis
Primary: Number of Patients With Change in Proteinuria or Serum Creatinine Over Treatment Period — 5 Participants
Chronic Kidney Disease
Primary: Whole Blood Platelet Aggregation to 0.5 Millimoles Arachidonic Acid — 21.0; 18.0; 0; 0 ohms
Antithrombin Deficiency, Congenital
Primary: Incidence of Thromboembolic Events Acute Deep Venous Thrombosis (DVT) and/or Thromboembolic Events Other Than Acute Deep Vein Thrombosis (DVT). — 1 participants
Renal Failure · End Stage Renal Disease · Vascular Access
Primary: Cumulative Number of Subjects With Adverse Events Indicating Possible Mechanical Failure or Weakness of the HAV — 0 participants
End Stage Renal Disease on Hemodialysis (Diagnosis)
Primary: Percentage of Subjects Reporting Clinically Significant Adverse Events - Medically-attended Adverse Events, Serious Adverse Events, and Immune-mediated Adverse Events of…
Sepsis
Primary: Mortality — 11 Participants
Thrombotic Microangiopathy
Primary: Participants With Thrombotic Microangiopathy (TMA) Response — 7 Participants
Dyskeratosis Congenita · Aplastic Anemia
Primary: Incidence of Neutrophil Engraftment — 100; 100; 96; 100 Percentage of participants
Thrombotic Thrombocytopenic Purpura (TTP)
Primary: Number of Participants With Acute Thrombotic Thrombocytopenic Purpura (TTP) Events During Prophylactic Treatment — 0; 0; 1 Participants
Dialysis Related Complication · Dialysis Hypotension · Hemodialysis-Induced Symptom
Primary: Medium Molecule Clearance — 53; 59.5 ml/min — p=0.4534
Improve Endothelial Function and Decrease Vascular Stenosis
Primary: Change in Baseline and 2 Week FMD/VP Measurements Between Sildenafil Group and Placebo Group — 10.8; 8.6 Change in FMD%
End Stage Renal Disease
Primary: Mean Partial Thromboplastin Time (PTT) at 15 Minutes — 38.4; 38.4; 45.4; 49.7 Seconds
Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
Primary: ADAMTS-13 Activity Levels — 0.1439; NA; NA; 0.5418 international units(IU)/ml